PMID- 29399699
OWN - NLM
STAT- MEDLINE
DCOM- 20180808
LR  - 20180808
IS  - 1791-2431 (Electronic)
IS  - 1021-335X (Linking)
VI  - 39
IP  - 3
DP  - 2018 Mar
TI  - The role of aldehyde dehydrogenase 1A1 in B-cell non-Hodgkin's lymphoma.
PG  - 1261-1268
LID - 10.3892/or.2018.6220 [doi]
AB  - Previously we showed that aldehyde dehydrogenase 1A1 (ALDH1A1) is a new mediator 
      for resistance of DLBCL to CHOP and a facility predictor of clinical prognosis.
      In the present study, knockdown and inhibitor of ALDH1A1 were applied to identify
      the role of ALDH1A1 in Raji cells. CCK-8 and clone formation assay were applied
      to determine the CHOP sensitivity and clone formation ability. Caspase
      colorimetric assay and Annexin V/FITC staining was performed to determine the
      degree of apoptosis. Western blot analysis was used to detect the NF-kappaB/STAT3
      signaling proteins and apoptotic-associated proteins. Real-time quantitative PCR 
      (RT-PCR) was used to identify the differential expression of ALDH1A1 between NHL 
      patients and healthy donors. We demonstrated that inhibition of ALDH1A1 increased
      the sensitivity of Raji cells to CHOP, as indicated by increased cytotoxicity,
      reduced clonogenicity, activated caspase-3/-9, decreased NF-kappaB/STAT3
      signaling and increased pro-apoptosis signaling, ad increased apoptosis rate.
      Moreover, we found high ALDH1A1 expression was associated with poor prognosis in 
      NHL patients. Our data revealed the critical role of ALDH1A1 in NHL and provides 
      a theoretical basis for the use of ALDH1A1 inhibitors in NHL patients.
FAU - Song, Ying-Hui
AU  - Song YH
AD  - Department of Oncology, Changsha Central Hospital, Hunan 410004, P.R. China.
FAU - Zhong, Mei-Zuo
AU  - Zhong MZ
AD  - Department of Oncology, Xiangya Hospital, Central South University, Changsha,
      P.R. China.
FAU - Chai, Qin
AU  - Chai Q
AD  - Department of Oncology, Changsha Central Hospital, Hunan 410004, P.R. China.
FAU - Gong, Kui-Yu
AU  - Gong KY
AD  - Department of Oncology, Changsha Central Hospital, Hunan 410004, P.R. China.
FAU - Tan, Xiao-Lang
AU  - Tan XL
AD  - Department of Oncology, Changsha Central Hospital, Hunan 410004, P.R. China.
FAU - Hu, Jin-Yue
AU  - Hu JY
AD  - Central Laboratory, Changsha Central Hospital, Changsha, P.R. China.
FAU - Wang, Gui-Hua
AU  - Wang GH
AD  - Department of Oncology, Changsha Central Hospital, Hunan 410004, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20180118
PL  - Greece
TA  - Oncol Rep
JT  - Oncology reports
JID - 9422756
RN  - 0 (NF-kappa B)
RN  - 0 (STAT3 Transcription Factor)
RN  - 0 (STAT3 protein, human)
RN  - 5J49Q6B70F (Vincristine)
RN  - 80168379AG (Doxorubicin)
RN  - 8N3DW7272P (Cyclophosphamide)
RN  - EC 1.2.1.3 (ALDH1A1 protein, human)
RN  - EC 1.2.1.3 (Aldehyde Dehydrogenase)
RN  - VB0R961HZT (Prednisone)
RN  - CHOP protocol
SB  - IM
MH  - Aldehyde Dehydrogenase/antagonists & inhibitors/metabolism/*physiology
MH  - Antineoplastic Combined Chemotherapy Protocols/pharmacology
MH  - Apoptosis
MH  - Cell Line, Tumor
MH  - Cyclophosphamide/pharmacology
MH  - Doxorubicin/pharmacology
MH  - Humans
MH  - Lymphoma, B-Cell/*enzymology/mortality
MH  - NF-kappa B/metabolism
MH  - Prednisone/pharmacology
MH  - Prognosis
MH  - STAT3 Transcription Factor/metabolism
MH  - Signal Transduction
MH  - Vincristine/pharmacology
EDAT- 2018/02/06 06:00
MHDA- 2018/08/09 06:00
CRDT- 2018/02/06 06:00
PHST- 2017/07/30 00:00 [received]
PHST- 2018/01/11 00:00 [accepted]
PHST- 2018/02/06 06:00 [pubmed]
PHST- 2018/08/09 06:00 [medline]
PHST- 2018/02/06 06:00 [entrez]
AID - 10.3892/or.2018.6220 [doi]
PST - ppublish
SO  - Oncol Rep. 2018 Mar;39(3):1261-1268. doi: 10.3892/or.2018.6220. Epub 2018 Jan 18.